Dekkun

Dekkun is operating in stealth mode with plans to develop pharmaceutical technologies. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts. Dekkun has developed DKN-01, a humanized monoclonal antibody for cancer treatment and the enhancement of cancer-related bone lesions.